search
Back to results

Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome

Primary Purpose

Reversible Cerebral Vasoconstriction Syndrome

Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
MRI brain
ASL-MRI brain
MRA brain
Sponsored by
University of Nottingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Reversible Cerebral Vasoconstriction Syndrome focused on measuring Reversible Cerebral Vasoconstriction Syndrome (RCVS), Arterial spin labeling (ASL) MRI

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patients aged 18-60 years old
  • Able to give informed written consent
  • Clinical presentation suggestive of RCVS
  • Able to understand the requirements of the study, including anonymous publication, and agree to co-operate with the study procedures

Exclusion Criteria:

  • Evidence of brain haemorrhage or significant brain pathology on Computed Tomography (CT) scan performed as standard National Health Service (NHS) care
  • Any history of significant cerebrovascular disease
  • Pregnancy or breastfeeding
  • MRI contraindications (e.g. metal implants or pacemaker) as indicated on the MRI Safety Screening Questionnaire
  • Significant claustrophobia

Sites / Locations

  • Clinical Neurology, Division of Clinical Neuroscience, University of Nottingham, UK

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ASL MRI and MRA

Arm Description

All participants will undergo ASL-MRI and MRA at three points; baseline, month 1, and month 3.

Outcomes

Primary Outcome Measures

Change in cortical cerebral blood flow (CBF) measured in ml/100g/min using ASL-MRI.
The process includes detailed imaging analysis.
Change in Circle of Willis arteries and major branches structure, this will be assessed by MRA and examined by a neuro-radiologist.
Correlation between vascular changes and perfusion levels will be measured.

Secondary Outcome Measures

RCVS complications, such as ischaemia, bleeding, and posterior reversible encephalopathy syndrome, will be assessed using standard MRI brain sequences.
Correlation between occurrence of these complications and perfusion levels will be measured.
Headache characteristics; participants will be questioned about their headache using a questionnaire as part of the case report form.
Correlation between headache characteristics and perfusion levels will be measured.

Full Information

First Posted
March 2, 2016
Last Updated
July 25, 2016
Sponsor
University of Nottingham
search

1. Study Identification

Unique Protocol Identification Number
NCT02756416
Brief Title
Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome
Official Title
Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Unknown status
Study Start Date
July 2016 (undefined)
Primary Completion Date
May 2017 (Anticipated)
Study Completion Date
May 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Nottingham

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to quantify perfusion, assess arterial vasoconstriction, and confirm reversibility using 3T ASL-MRI and MRA in 10 patients with suspected RCVS. Acquiring these data at multiple time points during RCVS progression, the investigators will assess the relationship between vasoconstriction and downstream perfusion and determine the role of these imaging techniques in early and accurate diagnosis of RCVS. The investigators also aim to investigate whether early imaging abnormalities can predict RCVS complications and clinical outcomes.
Detailed Description
Reversible Cerebral Vasoconstriction Syndrome (RCVS) is a group of conditions characterised by prolonged but reversible multifocal narrowing of the cerebral arteries. It presents typically as acute severe headache, usually recurrent and thunderclap in character, with or without additional symptoms and signs. Adverse complications associated with RCVS can be devastating especially if not recognised early; depending on the degree of vasoconstriction, RCVS may be associated with cortical subarachnoid haemorrhage (in approximately 34% of patients), ischaemic infarction (6-39% of patients), or concomitant posterior reversible encephalopathy syndrome (PRES, 9-38% of patients). RCVS may also present as parenchymal brain haemorrhage in 20% of cases. The data on complications rate highlight the uncertainty about the condition and indicate need for more research to better characterise the evolution of the pathology; hence need for this study as it is prospective and longitudinal. The hallmark of RCVS is vasoconstriction seen on vascular imaging scans and typically reverses within 3 months. Prevalence of radiological vasoconstriction seen on magnetic resonance angiography (MRA) in RCVS is reported to be between 60-90% and typically appears as diffuse segmental constriction of large and medium sized vessels lasting 4-12 weeks. The main advantage of MRA is that it can be performed without the use of a radioactive tracer, thus providing a safe method for repeat observations of vascular pathology. Imaging is often negative in first 4-5 days following the onset of headache; The mean time to detect abnormality on vascular imaging has been reported as 8 days after headache onset. RCVS symptoms usually resolves by 1 month after presentation, however the adverse complications associated with RCVS may have lasting consequences as described above. Magnetic resonance imaging (MRI) is an excellent tool for characterising brain changes during the progression and resolution of RCVS. Standard structural images can identify complications of RCVS, such as bleeding, ischaemia, and PRES. Finally, Arterial Spin Labeling (ASL) MRI can be used to non-invasively quantify perfusion of brain tissue, providing a measure of the impact of upstream arterial vasoconstriction on local cortical regions. Cortical perfusion has not yet been extensively studied in RCVS; at time of writing, only two case reports have been published. Rosenbloom and Singhal reported a case of RCVS induced by carotid endarterectomy following a frontal lobe ischaemic stroke. Perfusion MRI showed unilateral hypo-perfusion, mainly affecting internal watershed areas with superficial cortical regions being relatively spared. In a second study, ASL-MRI was performed on a 50-year-old man with RCVS who presented with severe recurrent headaches and neurological deficits (localising to the right hemisphere). ASL-MRI demonstrated significant hypo-perfusion in the right parieto-occipital lobe, but no infarct was seen on diffusion imaging. At 12 weeks, there was complete resolution of cerebral vasoconstriction on angiography and normal perfusion findings on ASL-MRI. These case studies suggest that perfusion MRI can offer an additional tool to confirm and understand RCVS. ASL-MRI is a non-invasive, radiation and contrast-free technique that can be performed at multiple time points to monitor changes in perfusion over the time period of RCVS resolution and assess response to potential therapeutics. One of the disadvantages of ASL-MRI is a low signal to noise ratio, this can be addressed by using high-field MRI at 3 Tesla (3T). In addition, 3T MRI can provide very good spatial resolution. The University of Nottingham represents one of the leading international research centres with experience in using high and ultra-high field MRI for investigating different neurological diseases such as multiple sclerosis and brain tumours with excellent results. Applying advanced non-invasive MRI techniques in this study will be a significant advantage as we investigate RCVS, understand the pathophysiology, and assess brain perfusion in multiple time points.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Reversible Cerebral Vasoconstriction Syndrome
Keywords
Reversible Cerebral Vasoconstriction Syndrome (RCVS), Arterial spin labeling (ASL) MRI

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ASL MRI and MRA
Arm Type
Experimental
Arm Description
All participants will undergo ASL-MRI and MRA at three points; baseline, month 1, and month 3.
Intervention Type
Device
Intervention Name(s)
MRI brain
Intervention Description
Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
Intervention Type
Device
Intervention Name(s)
ASL-MRI brain
Intervention Description
ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
Intervention Type
Device
Intervention Name(s)
MRA brain
Intervention Description
MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
Primary Outcome Measure Information:
Title
Change in cortical cerebral blood flow (CBF) measured in ml/100g/min using ASL-MRI.
Description
The process includes detailed imaging analysis.
Time Frame
Baseline, month 1, and month 3
Title
Change in Circle of Willis arteries and major branches structure, this will be assessed by MRA and examined by a neuro-radiologist.
Description
Correlation between vascular changes and perfusion levels will be measured.
Time Frame
Baseline, month 1, and month 3
Secondary Outcome Measure Information:
Title
RCVS complications, such as ischaemia, bleeding, and posterior reversible encephalopathy syndrome, will be assessed using standard MRI brain sequences.
Description
Correlation between occurrence of these complications and perfusion levels will be measured.
Time Frame
Baseline, month 1, and month 3
Title
Headache characteristics; participants will be questioned about their headache using a questionnaire as part of the case report form.
Description
Correlation between headache characteristics and perfusion levels will be measured.
Time Frame
Baseline, month 1, and month 3

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients aged 18-60 years old Able to give informed written consent Clinical presentation suggestive of RCVS Able to understand the requirements of the study, including anonymous publication, and agree to co-operate with the study procedures Exclusion Criteria: Evidence of brain haemorrhage or significant brain pathology on Computed Tomography (CT) scan performed as standard National Health Service (NHS) care Any history of significant cerebrovascular disease Pregnancy or breastfeeding MRI contraindications (e.g. metal implants or pacemaker) as indicated on the MRI Safety Screening Questionnaire Significant claustrophobia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nikos Evangelou, FRCP, D.Phil
Phone
00441159709735
Email
nikos.evangelou@nottingham.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Yasser Falah, MBChB, MRCP
Phone
00441158231082
Email
yasser.falah@nottingham.ac.uk
Facility Information:
Facility Name
Clinical Neurology, Division of Clinical Neuroscience, University of Nottingham, UK
City
Nottingham
State/Province
Nottinghamshire
ZIP/Postal Code
NG7 2UH
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nikos Evangelou, FRCP, D.Phil
Phone
00441159709735
Email
nikos.evangelou@nottingham.ac.uk
First Name & Middle Initial & Last Name & Degree
Yasser Falah, MBChB, MRCP
Phone
00441158231082
Email
yasser.falah@nottingham.ac.uk
First Name & Middle Initial & Last Name & Degree
Nikos Evangelou, FRCP, D.Phil

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
17200220
Citation
Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007 Jan 2;146(1):34-44. doi: 10.7326/0003-4819-146-1-200701020-00007.
Results Reference
background
PubMed Identifier
18025032
Citation
Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007 Dec;130(Pt 12):3091-101. doi: 10.1093/brain/awm256. Epub 2007 Nov 19.
Results Reference
background
PubMed Identifier
25593203
Citation
Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible Cerebral Vasoconstriction Syndrome, Part 1: Epidemiology, Pathogenesis, and Clinical Course. AJNR Am J Neuroradiol. 2015 Aug;36(8):1392-9. doi: 10.3174/ajnr.A4214. Epub 2015 Jan 15.
Results Reference
background
PubMed Identifier
25858343
Citation
Bernard KR, Rivera M. Reversible Cerebral Vasoconstriction Syndrome. J Emerg Med. 2015 Jul;49(1):26-31. doi: 10.1016/j.jemermed.2015.01.012. Epub 2015 Apr 7.
Results Reference
background
PubMed Identifier
20936928
Citation
Sattar A, Manousakis G, Jensen MB. Systematic review of reversible cerebral vasoconstriction syndrome. Expert Rev Cardiovasc Ther. 2010 Oct;8(10):1417-21. doi: 10.1586/erc.10.124.
Results Reference
background
PubMed Identifier
24087801
Citation
Lee R, Ramadan H, Bamford J. Reversible cerebral vasoconstriction syndrome. J R Coll Physicians Edinb. 2013;43(3):225-8. doi: 10.4997/JRCPE.2013.307.
Results Reference
background
PubMed Identifier
25511128
Citation
Calic Z, Cappelen-Smith C, Zagami AS. Reversible cerebral vasoconstriction syndrome. Intern Med J. 2015 Jun;45(6):599-608. doi: 10.1111/imj.12669.
Results Reference
background
PubMed Identifier
23245274
Citation
Mortimer AM, Bradley MD, Stoodley NG, Renowden SA. Thunderclap headache: diagnostic considerations and neuroimaging features. Clin Radiol. 2013 Mar;68(3):e101-13. doi: 10.1016/j.crad.2012.08.032. Epub 2012 Dec 11.
Results Reference
background
PubMed Identifier
24643327
Citation
Dilli E. Thunderclap headache. Curr Neurol Neurosci Rep. 2014 Apr;14(4):437. doi: 10.1007/s11910-014-0437-9.
Results Reference
background
PubMed Identifier
25614476
Citation
Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible Cerebral Vasoconstriction Syndrome, Part 2: Diagnostic Work-Up, Imaging Evaluation, and Differential Diagnosis. AJNR Am J Neuroradiol. 2015 Sep;36(9):1580-8. doi: 10.3174/ajnr.A4215. Epub 2015 Jan 22.
Results Reference
background
PubMed Identifier
17494670
Citation
Rosenbloom MH, Singhal AB. CT angiography and diffusion-perfusion MR imaging in a patient with ipsilateral reversible cerebral vasoconstriction after carotid endarterectomy. AJNR Am J Neuroradiol. 2007 May;28(5):920-2.
Results Reference
background
PubMed Identifier
25238101
Citation
Komatsu T, Kimura T, Yagishita A, Takahashi K, Koide R. A case of reversible cerebral vasoconstriction syndrome presenting with recurrent neurological deficits: Evaluation using noninvasive arterial spin labeling MRI. Clin Neurol Neurosurg. 2014 Nov;126:96-8. doi: 10.1016/j.clineuro.2014.08.023. Epub 2014 Aug 30. No abstract available.
Results Reference
background

Learn more about this trial

Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome

We'll reach out to this number within 24 hrs